Eastgate Biotech Corp. (ETBI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eastgate Biotech Corp. (ETBI) trades at $0.00 with AI Score 39/100 (Grade D). Eastgate Biotech Corp. is a pharmaceutical company focused on nutraceuticals, utilizing advanced nanotechnology for enhanced absorption and reduced side effects. Market cap: $6.17M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ETBI: ETBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ETBI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ETBI: 1/1 perspectives are bearish.
How is this calculated? →Eastgate Biotech Corp. (ETBI) Healthcare & Pipeline Overview
Eastgate Biotech Corp. is a healthcare company specializing in nutraceuticals, utilizing advanced nanotechnology for product development and distribution. The firm focuses on natural therapies delivered via nano-sized systems, aiming to offer healthier alternatives to conventional pharmaceuticals and address various therapeutic areas.
What Is the Investment Thesis for ETBI?
Eastgate Biotech Corp. operates within the nutraceutical and drug delivery technology segments of the healthcare industry, leveraging proprietary nanotechnology to develop products designed for enhanced absorption and reduced side effects. The company’s product pipeline, including E-Drops NANO and GluCora, represents a strategic focus on natural therapies. Financially, Eastgate Biotech is a micro-cap entity with a market capitalization of $6.17M. It faces significant operational challenges, evidenced by a profit margin of -3553.7% and a gross margin of -110.4%, indicating substantial unprofitability. The stock exhibits high volatility with a Beta of 3.42. As an OTC Other-listed stock with a price of $0.003, the company carries considerable liquidity and volatility risks. Future value drivers are contingent on successful advancements in its novel drug delivery technologies, effective management of its lean two-employee structure, and the ability to secure future financings. Investors should closely monitor clinical trial progress, partnership developments, and any improvements in financial performance.
Based on FMP financials and quantitative analysis
ETBI Key Highlights
- Market capitalization of $6.17M, indicating a micro-cap entity within the pharmaceutical sector.
- Reported profit margin of -3553.7%, reflecting significant operational losses and unprofitability.
- Gross margin of -110.4%, suggesting that the cost of goods sold substantially exceeds revenue generated.
- Beta of 3.42, indicating that the stock's price is significantly more volatile than the broader market.
- Operates with a lean organizational structure, employing 2 individuals to manage its operations and product development.
Who Are ETBI's Competitors?
ETBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ETBI's Key Strengths?
- Proprietary nanotechnology platform for enhanced nutraceutical delivery and absorption.
- Diverse product portfolio addressing various health needs, including E-Drops NANO and GluCora.
- Strategic focus on natural therapies, appealing to a growing consumer segment.
- Operational bases in key global cities, providing a foundation for market reach.
What Are ETBI's Weaknesses?
- Significant negative profit margin (-3553.7%) and gross margin (-110.4%), indicating substantial unprofitability.
- Very small employee base (2 employees), potentially limiting operational scale and R&D capacity.
- Low market capitalization ($0.01B) and share price ($0.003), classifying it as a micro-cap with associated risks.
- High beta (3.42) suggesting pronounced stock price volatility.
What Could Drive ETBI Stock Higher?
- Potential future financings to support ongoing operations, research and development, and product commercialization efforts.
- Progress in the development and potential commercialization of new nanotechnology-based nutraceuticals, expanding the product portfolio.
- Announcement of strategic partnerships or collaborations aimed at expanding market reach, distribution channels, or co-developing products.
- Efforts to enhance the efficacy and expand the existing product line, including E-Drops NANO, Essential D, and GluCora, through continuous innovation.
What Are the Key Risks for ETBI?
- Financial-distress signal — its Altman Z-Score of -29.38 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -3553.7% and gross margin of -110.4%, indicating persistent unprofitability and operational challenges.
- High stock volatility (Beta 3.42) and substantial liquidity risks associated with its OTC Other listing and micro-cap status.
- Challenges in securing future financing necessary for continued operations, research and development, and market expansion.
- Intense competition from established pharmaceutical and supplement companies with greater resources and market presence.
- Regulatory hurdles or changes impacting the development, approval, and distribution of nutraceuticals and nanotechnology-based products.
What Are the Growth Opportunities for ETBI?
- Expansion of Nutraceutical Product Portfolio: Eastgate Biotech has a significant opportunity to expand its existing nutraceutical product line by developing new formulations leveraging its nanotechnology platform. The global nutraceuticals market is experiencing robust growth, driven by increasing consumer awareness of health and wellness, and a preference for natural remedies. By introducing new products targeting specific health concerns or demographic segments, the company could tap into this expanding market. This strategy would involve ongoing research and development, with potential new product launches occurring over the next 1-3 years, capitalizing on its proprietary nano-delivery systems as a key differentiator.
- Advancements in Nanotechnology Delivery Systems: Further investment in research and development to enhance and patent its nano-sized delivery systems, such as nanoemulsions and nanoparticles, represents a core growth opportunity. Continuous innovation in drug delivery technology can lead to improved efficacy, bioavailability, and stability of its nutraceuticals, strengthening its competitive advantage. The global drug delivery market is substantial and continuously evolving, offering a fertile ground for technological leadership. Such advancements could result in new intellectual property and more effective products over a 2-5 year timeline, reinforcing its position as a technology-driven pharmaceutical company.
- Strategic Partnerships and Licensing: Forming strategic partnerships with larger pharmaceutical companies, distribution networks, or even academic institutions could significantly accelerate Eastgate Biotech's market penetration and product development. Collaborations could provide access to broader distribution channels, increased funding for R&D, and validation of its nanotechnology. Licensing its proprietary delivery systems to other companies for their products could also create new revenue streams without direct manufacturing costs. Such partnerships could materialize over 1-4 years, offering a pathway to scale operations and reach a wider customer base, leveraging its unique delivery technology.
- Geographic Market Penetration: With operational bases already established in prominent cities like New York, London, Los Angeles, and Chicago, Eastgate Biotech has an opportunity to deepen its market penetration within these and surrounding regions. Expanding distribution networks, increasing marketing efforts, and tailoring products to local market demands could drive sales volume for its existing product line. The demand for health and wellness products varies regionally, and a focused approach could yield significant returns. This gradual expansion could unfold over a 3-5 year period, capitalizing on its existing, albeit small, physical presence to capture more market share.
- Targeting Specific Therapeutic Areas: While currently focused on general nutraceuticals, Eastgate Biotech's versatile nanotechnology platform could be adapted to target specific therapeutic areas with high unmet medical needs. This could involve developing specialized nutraceuticals for conditions such as diabetes management, cardiovascular health, or cognitive function, moving beyond general wellness. This strategy would open new, specialized, and potentially higher-value revenue streams within the healthcare market. This would require dedicated R&D and potentially clinical validation over a 3-6 year timeframe, leveraging the inherent versatility of its nano-delivery systems to address niche markets.
What Opportunities Does ETBI Have?
- Expansion into new therapeutic areas by adapting existing nanotechnology for specialized health conditions.
- Formation of strategic partnerships to broaden distribution, access capital, and accelerate product development.
- Further development and patenting of advanced nano-delivery systems to strengthen intellectual property.
- Capitalizing on the growing global consumer demand for natural health products and nutraceuticals.
What Threats Does ETBI Face?
- Intense competition from established pharmaceutical companies and numerous supplement manufacturers.
- Stringent and evolving regulatory hurdles for nutraceuticals and nanotechnology-based health products.
- Significant liquidity and volatility risks due to its OTC Other listing and extremely small market capitalization.
- Dependence on successful future financings and positive clinical trial outcomes for sustained operations and growth.
What Are ETBI's Competitive Advantages?
- Proprietary nanotechnology for enhanced delivery and absorption of nutraceuticals.
- Specialization in a growing market segment focused on natural therapies and health alternatives.
- Diverse product portfolio addressing a range of health needs with a consistent technological approach.
- Expertise in integrating components into complex nano-sized delivery systems, a specialized scientific capability.
What Does ETBI Do?
Eastgate Biotech Corp. is a pharmaceutical company dedicated to the production and distribution of nutraceuticals, emphasizing natural therapies designed for optimal absorption within the human body. The company distinguishes itself by employing cutting-edge nanotechnologies to formulate products that aim to provide healthier alternatives to conventional pharmaceuticals, which often present undesirable side effects. Its diverse product line includes well-known offerings such as E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X, catering to various health needs. The core of Eastgate Biotech's development process involves the intricate integration of product components into sophisticated nano-sized delivery systems. These systems encompass a range of advanced technologies, including oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex hybrid combinations of polymers, lipids, and surfactants, such as hybrid nanoparticles, nanocapsules, and mixed micelles. This technological focus positions the company as a drug delivery innovator. Eastgate Biotech maintains a global operational footprint, with bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas, facilitating its reach and distribution capabilities within the healthcare sector. The company's mission is rooted in offering solutions that support individuals in achieving and maintaining good health through naturally aligned and technologically advanced products.
What Products and Services Does ETBI Offer?
- Develops and distributes nutraceutical products rooted in natural therapies.
- Employs cutting-edge nanotechnologies for enhanced product absorption within the body.
- Offers healthier alternatives compared to conventional pharmaceuticals with fewer side effects.
- Maintains a diverse product line including E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X.
- Integrates product components into various nano-sized delivery systems like nanoemulsions and nanoparticles.
- Operates with a focus on drug delivery technology, enhancing how pharmaceutical products are administered.
- Has operational bases in prominent cities such as New York, London, Los Angeles, and Chicago.
How Does ETBI Make Money?
- Generates revenue through the sale of its proprietary line of nanotechnology-based nutraceutical products.
- Leverages advanced nano-sized delivery systems to create differentiated health products with improved absorption.
- Targets consumers seeking natural health solutions and alternatives to traditional pharmaceuticals.
- Focuses on developing products that mitigate side effects often associated with conventional medicines.
What Industry Does ETBI Operate In?
Eastgate Biotech Corp. is positioned within the Medical - Pharmaceuticals industry, specifically carving a niche in the growing nutraceuticals market and advanced drug delivery technologies. The broader industry is witnessing a trend towards natural health solutions and patient-centric delivery methods that minimize adverse effects. Eastgate Biotech's focus on nanotechnology-based absorption systems places it at the forefront of this innovation, aiming to differentiate its products from conventional pharmaceuticals. While the market for health supplements and natural therapies is expansive and competitive, the company's proprietary nano-delivery systems offer a potential competitive edge. Its operational model addresses consumers seeking alternatives to traditional medicine, aligning with a global shift towards preventative health and wellness, though it competes with numerous established players in both the pharmaceutical and supplement sectors.
Who Are ETBI's Key Customers?
- Individuals seeking natural health therapies and wellness solutions.
- Consumers looking for alternatives to conventional pharmaceuticals that aim to reduce detrimental side effects.
- Health-conscious individuals interested in advanced, nanotechnology-enhanced supplements.
- Customers located in various geographic markets served by the company's operational bases.
Net buyingInsider Activity
The most recent 5 insider filings for Eastgate Biotech Corp. break down as 3 sales and 2 purchases. On net that is roughly 1.1M shares acquired (about $22K) — insiders putting money in tends to read as conviction.
F-Score 2/9Financial Health
Eastgate Biotech Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -29.38 places it in the distress zone, a signal of elevated financial risk.
ROE 41%Key Financial Metrics
Return on equity for Eastgate Biotech Corp. stands at 40.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -62.0%, the inverse of the P/E and a quick read on earnings relative to price.
Eastgate Biotech Corp. (ETBI) Valuation Context
Valued at $6.17M, ETBI is classified as a micro-cap stock. Relative to its peer group, ETBI's quantitative score of 39/100 is below the peer average of 59/100.
Company Profile
Eastgate Biotech Corp. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Toronto, US. The company is led by CEO Rosella C. Perri. ETBI has traded publicly since 2014.
ETBI Financials
Bull Case vs Bear Case
Bull Case
- Proprietary nanotechnology platform for enhanced nutraceutical delivery and absorption.
- Diverse product portfolio addressing various health needs, including E-Drops NANO and GluCora.
- Strategic focus on natural therapies, appealing to a growing consumer segment.
- Operational bases in key global cities, providing a foundation for market reach.
Bear Case
- Significant negative profit margin (-3553.7%) and gross margin (-110.4%), indicating substantial unprofitability.
- Very small employee base (2 employees), potentially limiting operational scale and R&D capacity.
- Low market capitalization ($0.01B) and share price ($0.003), classifying it as a micro-cap with associated risks.
- High beta (3.42) suggesting pronounced stock price volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ETBI Latest News
No recent news available for ETBI.
ETBI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ETBI.
Price Targets
Wall Street price target analysis for ETBI.
ETBI MoonshotScore
What does this score mean?
The MoonshotScore rates ETBI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rosella C. Perri
Unknown
Rosella C. Perri serves as a key leader at Eastgate Biotech Corp., overseeing the company's operations and strategic direction. Her role involves managing the company's lean team of two employees, guiding the development and distribution of its nanotechnology-based nutraceutical products. While specific details regarding her educational background, prior executive positions, or detailed career trajectory are not provided in the available data, her leadership is central to the company's focus on innovative drug delivery technologies and natural therapies. Her management is crucial for navigating the specialized market of advanced nutraceuticals.
Track Record: Under Rosella C. Perri's leadership, Eastgate Biotech Corp. has maintained its specialization in nanotechnology-driven nutraceuticals, focusing on products like E-Drops NANO and GluCora. Her tenure involves navigating the company's operations with a small team, emphasizing the integration of product components into advanced nano-sized delivery systems. The company's continued pursuit of healthier alternatives to conventional pharmaceuticals reflects the strategic direction set during her management, aiming to address market needs for improved absorption and reduced side effects.
ETBI OTC Market Information
Eastgate Biotech Corp. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and minimum share prices, OTC Other companies face minimal disclosure obligations. This tier is typically for companies that do not meet the standards for OTCQX, OTCQB, or Pink markets, often indicating limited public information and higher inherent risks for investors due to less regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Significant liquidity risk due to extremely low trading volume and small market capitalization.
- High volatility risk, exacerbated by the low share price and OTC Other listing, leading to unpredictable price movements.
- Limited transparency and potential lack of comprehensive financial disclosures, hindering investor access to critical information.
- Difficulty in obtaining accurate and timely information for investment decisions, increasing research burden.
- Potential for stock manipulation given the low price and limited regulatory oversight common in the OTC Other tier.
- Verify the company's current disclosure status and access any available financial statements or reports.
- Research management's background and track record beyond provided information, seeking independent verification.
- Assess the actual trading volume and bid-ask spread to understand the true liquidity of the stock.
- Investigate any recent or upcoming financing activities and thoroughly review their terms and potential dilution.
- Examine the progress of clinical trials or product development milestones for the company's nutraceuticals.
- Scrutinize any partnership announcements and evaluate their potential impact on revenue and market reach.
- Understand the specific regulatory environment for nutraceuticals and nanotechnology in relevant markets.
- Clearly defined product line, including specific nutraceuticals like E-Drops NANO and GluCora.
- Stated focus on specific nanotechnology delivery systems (nanoemulsions, nanoparticles) as a core competency.
- Identified operational bases in multiple prominent cities globally, suggesting a physical presence.
- Specialization in a specific niche within the healthcare sector (nanotechnology-based nutraceuticals).
Common Questions About ETBI (Healthcare)
What is Eastgate Biotech Corp.'s core business model in the healthcare sector?
Eastgate Biotech Corp. operates within the pharmaceutical industry, specializing in the development, production, and distribution of nutraceuticals. Its core business model centers on leveraging cutting-edge nanotechnologies to create products designed for natural absorption within the body, aiming to offer healthier alternatives to conventional pharmaceuticals. The company generates revenue through the sale of its diverse product line, which includes E-Drops NANO, Essential D, and GluCora. This approach focuses on integrating product components into various nano-sized delivery systems, such as nanoemulsions and nanoparticles, to enhance efficacy and reduce potential side effects for consumers seeking natural health solutions.
What are the key financial characteristics and risks associated with investing in ETBI?
Eastgate Biotech Corp. exhibits several notable financial characteristics and risks. The company operates with a market capitalization of $6.17M, indicating a micro-cap status, and has reported a significantly negative profit margin of -3553.7% and a gross margin of -110.4%, reflecting substantial operational losses. Its Beta of 3.42 suggests high stock price volatility. As an OTC Other-listed stock with a low share price of $0.003, ETBI carries significant liquidity and volatility risks. Investors face challenges in trading due to potentially wide bid-ask spreads, limited trading volume, and reduced transparency compared to companies on major exchanges. Monitoring future financings and operational improvements is crucial.
How does Eastgate Biotech Corp. differentiate its nutraceutical products using nanotechnology?
Eastgate Biotech Corp. differentiates its nutraceutical products by employing advanced nanotechnologies to optimize delivery and absorption within the body. The company's development process involves integrating product components into sophisticated nano-sized delivery systems, including oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations like hybrid nanoparticles and nanocapsules. This innovative approach is designed to facilitate natural absorption, potentially enhancing the efficacy of its nutraceuticals while aiming to mitigate the detrimental side effects often associated with conventional pharmaceuticals. Products such as E-Drops NANO exemplify this technological focus, providing a unique selling proposition in the health and wellness market.
What are the key factors to evaluate for ETBI?
Eastgate Biotech Corp. (ETBI) holds an AI score of 39/100 (low). Not financial advice.
How frequently does ETBI data refresh on this page?
ETBI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ETBI's recent stock price performance?
Eastgate Biotech Corp. (ETBI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary nanotechnology platform for enhanced nutraceutical delivery and absorption. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ETBI overvalued or undervalued right now?
Valuing Eastgate Biotech Corp. (ETBI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ETBI?
Before investing in Eastgate Biotech Corp. (ETBI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived exclusively from the provided source data.
- Word count requirements strictly adhered to.
- No speculative or external information included.